New RSV vaccine study targets those over 80
⭐️ VACCINE ⭐️
Recruiting now
This study looks at how well the approved RSV vaccine Arexvy works in people aged 80 and older compared to those aged 60-65. Researchers will measure immune responses and side effects. The goal is to see if the vaccine protects the oldest and frailest adults as effectively as you…
Phase: PHASE3 • Sponsor: Karin Karin Loré • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 07:52 UTC